{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Pacira BioSciences Mails Letter to Stockholders - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"PggF9NmVVP\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-mails-letter-to-stockholders\/\">Pacira BioSciences Mails Letter to Stockholders<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-mails-letter-to-stockholders\/embed\/#?secret=PggF9NmVVP\" width=\"600\" height=\"338\" title=\"&#8220;Pacira BioSciences Mails Letter to Stockholders&#8221; &#8212; Market Newsdesk\" data-secret=\"PggF9NmVVP\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Details Success of Pacira\u2019s 5&#215;30 Strategy and Solid First Quarter 2026 Results\u00a0 Reiterates Board\u2019s Unanimous Recommendation that Stockholders Vote \u201cFOR\u201d the Election of Pacira\u2019s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 05, 2026 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX) (the \u201cCompany\u201d or \u201cPacira\u201d), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has mailed a letter to stockholders in connection with the Company\u2019s 2026 Annual Meeting of Stockholders (the \u201cAnnual Meeting\u201d), scheduled to be held on June 9, 2026. Stockholders of record as of April 22, 2026 will be entitled to vote at the Annual Meeting. Highlights of the letter &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzcyMyM3NTgyMjk3IzIwMDg5MTE="}